AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
CSL’s latest result suggests the worst may be over
Relief replaces disappointment but can growth return?
stocks
ASX listed pharma boosted by weight loss drugs
GLP-1 momentum drives earnings for narrow moat share.
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,271.40 | 6.30 | 0.07% |
| CAC 40 | 8,334.50 | 66.68 | -0.79% |
| DAX 40 | 26,258.11 | 311.88 | -1.17% |
| Dow JONES (US) | 53,185.90 | 374.09 | -0.70% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,566.99 | 17.80 | -0.07% |
| NASDAQ | 26,370.89 | 31.54 | -0.12% |
| Nikkei 225 | 66,311.93 | 93.63 | -0.14% |
| NZX 50 Index | 13,842.40 | 74.90 | -0.54% |
| S&P 500 | 7,686.14 | 25.62 | -0.33% |
| S&P/ASX 200 | 9,076.00 | 10.40 | 0.11% |
| SSE Composite Index | 3,986.30 | 34.12 | 0.86% |